By


Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson’s Disease

FDA indicates the Company may proceed with the Phase 3 clinical study of buntanetap for the treatment of Parkinson’s disease

See more here

By


Immunome’s COVID-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants* in the US, BA.4/5 and BA.2.12.1

– IMM-BCP-01 neutralized BA.4/.5 and BA.2.12.1 subvariants in pseudovirus testing 

– IMM-BCP-01 currently in Phase 1b clinical testing with topline data expected in 2H 2022 

See more here

By


Bainbridge Health and Purdue University Collaborate to Advance the Infusion Pump Industry

Collaboration will form the leading infusion pump management platform and community in the United States

See more here

By


Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by Infections

Annovis Bio’s Current Intellectual Property Portfolio Covers the Use of Buntanetap, the Company’s Lead Compound, to Treat Neurodegenerative Diseases

With this Recent Filing, the Company Seeks Protection for Buntanetap to Treat Infection-Dependent Neurological Injuries

See more here

By


Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19

– First study subject has been dosed in a single dose/dose escalation study of recently diagnosed COVID-19 patients –

– Study will evaluate safety as the primary end point with pharmacokinetics (PK) and virology as secondary assessments –

See more here

By


Concarlo Expands Executive Leadership Team with the Appointment of Dr. Krishna Allamneni as Chief Development Officer

Industry veteran will help accelerate Company’s drive to create transformative therapies for drug resistant cancers by controlling the p27 target

See more here

By


Renovacor Announces Data from Pilot Pig Study Showing Successful Cardiac Transduction with REN-001 Delivered Via Low-Dose Retrograde Coronary Sinus Infusion Published in Journal of the American College of Cardiology: Basic to Translational Research

REN-001 delivered locally via low-dose retrograde coronary sinus infusion demonstrated robust, diffuse cardiomyocyte transduction in a large animal heart

See more here

By


ENB Therapeutics Announces Orphan Drug Designation Granted by FDA for ENB-003 for the Treatment of Pancreatic Cancer

ENB-003 is a first in class small molecule therapeutic selectively targeting the ETB receptor – a novel immune checkpoint

See more here